[Dynamics of structural-functional parameters of cardiovascular system during use of complex therapy of women with type 2 diabetes mellitus].
Aim of the work was to study dynamics of parameters of cardiovascular system in women during use of various sugar lowering drugs in complex multifactorial therapy of type 2 diabetes mellitus (DM). We included in this 12 months study 182 women older than 55 years with type 2 DM, abdominal obesity and artrerial hypertension (AH). All women received angiotensin converting enzyme inhibitors and statins. As sugar lowering drugs we used metformin (n = 46), metformin with glyclazide (n = 47), monotherapy with insulin (n = 45). Long-term use of metformin in complex multifactorial therapy of women with decompensated type 2 diabetes DM, AH and abdominal obesity provides improvement of carbohydrate and lipid metabolism, lowering of arterial pressure, diminishment of albuminuria, diastolic dysfunction, and stiffness of left ventricular myocardium. The use of combination of metformin with glyclazide MB provides advantages in lowering of insulin resistance, contol glycemia, and lessening of hypertrophy of left ventricular myocardium.
Onuchin
S G
SG
Elsukova
O S
OS
Solov'ev
O V
OV
Onuchina
E L
EL
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D003627:Data Interpretation, Statistical; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005907:Gliclazide / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D007333:Insulin Resistance; D008297:Male; D008687:Metformin / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D056128:Obesity, Abdominal / Q000150:complications; D012307:Risk Factors; D013997:Time Factors
D000806:Angiotensin-Converting Enzyme Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D008687:Metformin; D005907:Gliclazide